UNIQURE NV (QURE) Stock Price, Quote, News and Overview
NASDAQ:QURE - Nasdaq - NL0010696654 - Common Stock - Currency: USD
QURE Quote, Performance and Key Statistics
13.7
+0.45 (+3.4%)
The current stock price of QURE is 13.7 USD. In the past month the price increased by 5.38%. In the past year, price increased by 173.45%.
QURE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.92 | 325.53B | ||
| AMGN | AMGEN INC | 13.12 | 146.46B | ||
| GILD | GILEAD SCIENCES INC | 13.24 | 127.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.77B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.41 | 64.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.11B | ||
| ARGX | ARGENX SE - ADR | 96.36 | 34.54B | ||
| ONC | BEIGENE LTD-ADR | 5.68 | 24.62B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.74B | ||
| BIIB | BIOGEN INC | 7.94 | 18.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.73B |
Related stock screener links
About QURE
Company Profile
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 209 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Company Info
UNIQURE NV
Paasheuvelweg 25a
Amsterdam NOORD-HOLLAND 1105 BP NL
CEO: Matthew Kapusta
Employees: 209
Phone: 31202406000
UNIQURE NV / QURE FAQ
What is the stock price of UNIQURE NV today?
The current stock price of QURE is 13.7 USD. The price increased by 3.4% in the last trading session.
What is the ticker symbol for UNIQURE NV stock?
The exchange symbol of UNIQURE NV is QURE and it is listed on the Nasdaq exchange.
On which exchange is QURE stock listed?
QURE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for UNIQURE NV stock?
20 analysts have analysed QURE and the average price target is 36.63 USD. This implies a price increase of 167.35% is expected in the next year compared to the current price of 13.7. Check the UNIQURE NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is UNIQURE NV worth?
UNIQURE NV (QURE) has a market capitalization of 749.80M USD. This makes QURE a Small Cap stock.
How many employees does UNIQURE NV have?
UNIQURE NV (QURE) currently has 209 employees.
What are the support and resistance levels for UNIQURE NV (QURE) stock?
UNIQURE NV (QURE) has a support level at 12.94 and a resistance level at 14.78. Check the full technical report for a detailed analysis of QURE support and resistance levels.
Is UNIQURE NV (QURE) expected to grow?
The Revenue of UNIQURE NV (QURE) is expected to grow by 8.22% in the next year. Check the estimates tab for more information on the QURE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy UNIQURE NV (QURE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of QURE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of QURE, evaluating the profitability, health, valuation and growth aspects
- UNIQURE NV (QURE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- UNIQURE NV (QURE) Sales and EPS estimates to see what analysts future expectations are.
- UNIQURE NV (QURE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- UNIQURE NV (QURE) Insider and Institutional Ownership to learn about the owners and their transactions.
- UNIQURE NV (QURE) Stock Chart to make your own analysis
- UNIQURE NV (QURE) Latest news and press-releases to stay up to date.
Does UNIQURE NV (QURE) stock pay dividends?
QURE does not pay a dividend.
What is the Price/Earnings (PE) ratio of UNIQURE NV (QURE)?
UNIQURE NV (QURE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.41).
What is the Short Interest ratio of UNIQURE NV (QURE) stock?
The outstanding short interest for UNIQURE NV (QURE) is 11.21% of its float. Check the ownership tab for more information on the QURE short interest.
QURE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to QURE. When comparing the yearly performance of all stocks, QURE is one of the better performing stocks in the market, outperforming 98.09% of all stocks.
QURE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to QURE. Both the profitability and financial health of QURE have multiple concerns.
QURE Financial Highlights
Over the last trailing twelve months QURE reported a non-GAAP Earnings per Share(EPS) of -4.41. The EPS increased by 29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.94% | ||
| ROE | -645.89% | ||
| Debt/Equity | 14.79 |
QURE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to QURE. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of 19.58% and a revenue growth 8.22% for QURE